Individual Peptide Profile
PE-22-28
A chemically stabilized analog of spadin, a naturally occurring peptide fragment of the protein sortilin. It was engineered to resist rapid enzymatic breakdown while preserving spadin's proposed activity at the TREK-1 potassium channel, a target of interest for rapid-acting antidepressant research. All published work is in animal models.
WHAT IT IS
Spadin, the parent peptide, is a naturally occurring fragment released from the protein sortilin. French researchers identified it in the mid-2000s and found that it blocked the TREK-1 potassium channel, a channel implicated in mood regulation and a target already linked to some antidepressant drug mechanisms.
Native spadin degrades quickly in the body, which limits its usefulness as a research tool and any future drug candidate. PE-22-28 is a shortened, chemically modified version designed to resist that breakdown while retaining the parent peptide's ability to block TREK-1.
It remains an experimental research compound. No spadin analog, including PE-22-28, has advanced into published human clinical testing.
WHAT RESEARCHERS ARE STUDYING IT FOR
Published animal and laboratory work has focused on:
- TREK-1 potassium channel blockade and downstream neuronal excitability changes
- Behavioral tests used as proxies for depression and anxiety-like states in rodents
- Onset speed compared with conventional antidepressant classes in animal models
- Stability and half-life improvements relative to native spadin
- Hippocampal signaling changes associated with mood-related channel activity
PROPOSED BIOLOGICAL MECHANISMS
TREK-1 is a two-pore-domain potassium channel that helps regulate how easily certain neurons fire. Blocking it is proposed to increase neuronal excitability in circuits linked to mood regulation, a mechanism distinct from how traditional serotonergic antidepressants work.
Animal studies report that spadin and PE-22-28 produce effects in standard rodent behavioral despair tests within a shorter timeframe than some conventional antidepressants, which is the basis for describing it as a rapid-acting candidate.
These mechanistic and behavioral findings come exclusively from rodent models and isolated tissue preparations, and have not been replicated or tested in human neurons or human trials.
AREAS OF RESEARCH INTEREST
- Whether TREK-1 blockade is a viable target for a distinct class of antidepressant
- Whether the rapid onset seen in rodent tests would hold up in human depression trials
- Whether a stabilized peptide analog can be developed into a deliverable drug candidate
- How selective PE-22-28 is for TREK-1 relative to other ion channels
WHAT THE EVIDENCE CURRENTLY SUGGESTS
The evidence base is small and entirely preclinical, originating mostly from the research groups that first characterized spadin and its stabilized analogs.
No randomized controlled trials, no human pharmacokinetic studies and no human safety data have been published for PE-22-28 or spadin.
FDA status: PE-22-28 is not an FDA-approved medication for any condition.
A promising target is not a proven drug
TREK-1 IS A HYPOTHESIS, NOT A TREATMENT
Ion channel targets like TREK-1 are genuinely interesting to mood-disorder researchers because they offer a mechanism different from existing antidepressant classes.
But an interesting molecular target with supportive rodent data is an early step in drug development, not a finished answer, and many promising preclinical antidepressant candidates never reach human testing or fail once they do.
Depression and anxiety are serious conditions best managed with treatments that have actual human trial evidence behind them.
Research Reality Check
What we know
PE-22-28 is a stabilized analog of spadin, reported in rodent studies to block the TREK-1 potassium channel and to produce rapid effects in standard antidepressant-screening behavioral tests.
What remains uncertain
Whether any of this translates to human depression treatment. There is no human trial data, no established human dosing, no known human pharmacokinetics and no long-term human safety information.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
PE-22-28 interests us because it represents a genuinely different mechanistic idea in mood research, an ion channel target rather than the usual serotonin-focused approach, and that kind of novelty is worth paying attention to.
If PE-22-28 or spadin research has come up in something you have read and you want to talk through what it actually shows, reach out to us. We are glad to work through your questions and look at what is happening in the peptide research space.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- PubMed: Spadin, a sortilin-derived peptide, antidepressant activity via TREK-1 channel blockade
- PubMed: PE-22-28 stabilized spadin analog pharmacology and behavior studies
- PubMed Central: TREK-1 potassium channel in mood disorders, review literature
- U.S. Food and Drug Administration: Drug Approval Process
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.